Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

July 29, 2018

Primary Completion Date

May 27, 2019

Study Completion Date

June 3, 2019

Conditions
Hepatitis B Infection
Interventions
BIOLOGICAL

Hepa-B

Incepta will manufacture a locally produced Hepatitis B vaccine named 'Hepa- B' which contain recombinant Hepatitis B surface antigen obtaine. This bulk is formulated to prepare finished dosage to manufacture large scale in fully GMP compliant plant. Incepta has conducted preclinical study at Bioneed, India. After successful completion of preclinical study, this non inferiority clinical trial with innovator product is needed for Licensure in Bangladesh.

BIOLOGICAL

Engerix B

.'Engerix B' is a recombinant DNA hepatitis B vaccine. It is sterile suspension of purified surface antigen of hepatitis B virus obtained by culturing genetically yeast cells (Saccharomyces cerevisiae cells), which carry the gene that codes for HBsAg

Trial Locations (1)

1216

Mirpur Field Office, Dhaka

All Listed Sponsors
lead

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

NCT03627507 - Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh. | Biotech Hunter | Biotech Hunter